venetoclax
No description yet: the sentence for this tag has not been written. 5 records carry it: 5 people.
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Andrew H. Wei Consultant Haematologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Professor, University of Melbourne · Peter MacCallum Cancer Centre Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML. | Acute myeloid leukaemia | none | aml, australia | ||
Barbara Eichhorst Professor of Medicine and Head of the CLL Outpatient Clinic, University Hospital Cologne; Secretary, German CLL Study Group · Uniklinik Köln (CIO) Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients. | Chronic lymphocytic leukaemia | none | cll, guidelines | ||
Courtney D. DiNardo Professor of Leukemia, MD Anderson Cancer Center · MD Anderson Cancer Center Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia. | Acute myeloid leukaemia | none | aml, trialist | ||
John F. Seymour Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital · Peter MacCallum Cancer Centre Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL. | Chronic lymphocytic leukaemia | none | cll, australia | ||
Kirsten Fischer Senior Physician and Study Coordinator, German CLL Study Group, University Hospital Cologne · Uniklinik Köln (CIO) Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment. | Chronic lymphocytic leukaemia | none | cll, fixed-duration |